News & Updates
Filter by Specialty:
POETYK trials highlight potential of novel drug for plaque psoriasis
The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.
POETYK trials highlight potential of novel drug for plaque psoriasis
11 Oct 2021
Study identifies risk factors for impaired BNT162b2 mRNA antibody response in lupus
Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.
Study identifies risk factors for impaired BNT162b2 mRNA antibody response in lupus
11 Oct 2021
ACE inhibitors, ARBs put brakes on emphysema progression, lung function decline in COPD
Angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear to be beneficial to chronic obstructive pulmonary disease (COPD) patients, with a recent study suggesting that the use of such drugs may slow down progression of emphysema and lung function decline.
ACE inhibitors, ARBs put brakes on emphysema progression, lung function decline in COPD
10 Oct 2021
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.
